MedPath

Madrigal Pharmaceuticals Reports Third-Quarter 2024 - GlobeNewswire

Subscribe Icon

Stay Updated with Our Daily Newsletter

Get the latest pharmaceutical insights, research highlights, and industry updates delivered to your inbox every day.

Related Topics

Madrigal's Rezdiffra Shows Promise in MASH Cirrhosis with Two-Year Data

Madrigal Pharmaceuticals reports Rezdiffra (resmetirom) demonstrates potential benefits in patients with compensated MASH cirrhosis (F4c).
Two-year data from the MAESTRO-NAFLD-1 trial shows a mean 6.7 kPa reduction in liver stiffness, the largest reported in this patient group.

MedMira's Reveal® G4 HIV-1/2 Rapid Test Achieves 100% Specificity in Clinical Trials; Awaits CLIA Waiver

MedMira's Reveal® G4 Rapid HIV-1/2 antibody test demonstrated 100% sensitivity and specificity in clinical trials, including reactivity in early HIV-2 infections.
The company is in the final phase of U.S. clinical trials to achieve CLIA waived approval for the Reveal® G4 HIV-1/2 rapid test, with an update expected in early 2025.

PolyPid's D-PLEX100 SHIELD II Trial Completes Patient Enrollment for Interim Analysis

PolyPid has completed enrollment of 430 patients in the SHIELD II Phase 3 trial of D-PLEX100, triggering an unblinded interim analysis.
The interim analysis outcome, expected later this quarter, could lead to early trial conclusion, sample size re-assessment, or continuation to planned recruitment.

InflaRx Advances Pipeline with Vilobelimab and INF904, Anticipates Key Milestones in 2025

InflaRx's Phase 3 trial of vilobelimab for pyoderma gangrenosum (PG) reached its 30-patient recruitment milestone, with an interim analysis expected by the end of Q2 2025.
A Phase 2a trial for INF904, targeting chronic spontaneous urticaria (CSU) and hidradenitis suppurativa (HS), is set to begin by the end of 2024, with initial data expected in summer 2025.

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Clinical Progress in NASH/MASH

Madrigal Pharmaceuticals reported $62.2 million in net sales for Rezdiffra in Q3 2024, marking a strong initial uptake in the U.S. market.
The company achieved early coverage goals, with over 80% of commercial lives covered for Rezdiffra, primarily relying on non-invasive tests for diagnosis.

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Advancement of NASH Cirrhosis Study

Madrigal Pharmaceuticals reported $62.2 million in net revenues for Q3 2024, driven by the U.S. launch of Rezdiffra for NASH/MASH.
The company's operating expenses increased to $178.5 million, reflecting commercial launch activities and increased headcount.

Madrigal Pharmaceuticals Reports Positive Q3 2024 Results and Advances NASH/MASH Programs

Madrigal Pharmaceuticals reported $62.2 million in net sales for Q3 2024, driven by the U.S. launch of Rezdiffra™ (resmetirom).
Rezdiffra achieved early coverage success, with over 80% of commercial lives covered and less than 5% requiring biopsy for diagnosis.

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Provides Corporate Updates

Madrigal Pharmaceuticals reported $62.2 million in net revenues for Q3 2024, driven by the U.S. launch of Rezdiffra (resmetirom) for nonalcoholic steatohepatitis (NASH)/metabolic dysfunction-associated steatohepatitis (MASH).
The company's Rezdiffra launch has achieved over 80% commercial coverage ahead of schedule, with growing adoption by prescribers and increasing patient numbers on therapy.

Madrigal Pharmaceuticals Reports Strong Rezdiffra Launch and Clinical Progress in NASH/MASH

Madrigal Pharmaceuticals reports $62.2 million in net sales for Rezdiffra™ in Q3 2024, marking a strong initial uptake in the U.S. market.
Rezdiffra achieves broad payer coverage, with over 80% of commercial lives covered, primarily relying on non-invasive tests for diagnosis.

Larimar Therapeutics Advances Nomlabofusp for Friedreich's Ataxia; Reports Q3 2024 Results

Larimar Therapeutics reported a Q3 2024 net loss of $15.5 million, with a strong cash position of $203.7 million, expected to last into 2026.
The company's lead program, nomlabofusp for Friedreich's ataxia, is progressing with a program update expected in mid-December 2024.

Reference News

[1]
Madrigal Pharmaceuticals Reports Third-Quarter 2024 - GlobeNewswire
globenewswire.com · Oct 31, 2024

Madrigal Pharmaceuticals reports Q3 2024 net sales of $62.2 million, with Rezdiffra™ coverage goal achieved early, cover...

© Copyright 2025. All Rights Reserved by MedPath
HomeTerms & ConditionsPrivacy Policy